跳至主要内容
临床试验/NCT00004827
NCT00004827已完成不适用

Study of Docosahexaenoic Acid (DHA) Supplementation in Patients With X-Linked Retinitis Pigmentosa

Retina Foundation of the Southwest0 个研究点目标入组 46 人开始时间: 1996年3月1日最近更新:
适应症
相关药物

试验速览

阶段
不适用
状态
已完成
入组人数
46

研究概览

简要总结

OBJECTIVES:

I. Evaluate the potential of nutritional docosahexaenoic acid (DHA) supplementation to normalize the level of DHA in red blood cells, and to retard the progression of visual function loss in patients with early stage X-linked retinitis pigmentosa.

详细描述

PROTOCOL OUTLINE: This is a randomized, parallel, double blind study. Patients receive 2 gel capsules per day of either docosahexaenoic acid (DHA) enriched oil or a placebo oil. Oral DHA supplementation continues daily for 3 years.

All patients are followed every 6 months for the 3 year duration of the study.

Completion date provided represents the completion date of the grant per OOPD records

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double

入排标准

性别
Male
接受健康志愿者
否

入选标准

  • •PROTOCOL ENTRY CRITERIA:
  • •-Disease Characteristics--
  • •Diagnosis of X-linked retinitis pigmentosa
  • •Early stage disease Sufficient cone function determined by recordable ERG (30 Hz amplitude; greater than 0.32 microvolts) Visual fields greater than 20 degrees Sufficient rod function (greater than 3.0 microvolts amplitude)
  • •Media clarity sufficient for fundus photography
  • •-Prior/Concurrent Therapy--
  • •No concurrent use of anticoagulant medication
  • •-Patient Characteristics--
  • •No chronic metabolic disease that may interfere with fatty acid metabolism
  • •No bleeding of clinical significance

排除标准

  • 未提供

研究者

申办方类型
Other

相似试验